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INTRODUCTION
Medical  care for  acute 
diseases requiring hospitalization 
varies between countries and 
often within the same country. 
The same acute diseases are 
treated in hospitals with different 
profiles of expertise, different bed 
bases for specialties and different 
guidelines. There are two major 
pathways for admission with 
acute diseases.
One of the pathways is 
organized care in high-volume 
specialized centers for specific 
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ABSTRACT
Aims: In this observational study, we investigated whether specialized care improves outcomes for acute 
pancreatitis (AP). 
Methods: Consecutive patients admitted to two university hospitals with AP were enrolled in this study 
between 1 January 2016 and 31 December 2016 (Center A: specialized center; Center B: general hospital). 
Data on demographic characteristics and AP etiology, severity, mortality and quality of care (enteral nutrition 
and antibiotic use) were extracted from the Hungarian Acute Pancreatitis Registry. An independent sample 
t-test, Mann–Whitney test, chi-squared test or Fisher’s test were used for statistical analyses. Costs of care 
were calculated and compared in the two models of care. 
Results: There were 355 patients enrolled, 195 patients in the specialized center (Center A) and 160 patients in 
the general hospital (Center B). There was no difference in mean age (57.02 ±17.16 vs. 57.31 ±16.50 P=0.872) 
and sex ratio (56% males vs. 57% males, P=0.837) between centres, allowing a comparison without selection 
bias. Center A had lower mortality (n=2, 1.03% vs. n=16, 6.25%, p=0.007), more patients received enteral 
feeding (n=179, 91.8%, vs. n=36, 22.5%, p<0.001) and fewer patients were treated with antibiotics (n=85, 
43.6% vs. n=123, 76.9%, p=0.001). In Center A the median length of hospitalization was shorter (Me 6, IQR 
5–9 vs. Me 8, IQR 6–11, p=0.02) and the costs of care were by 25% lower.
Conclusion: Our data suggests that treatment of AP in specialized centers reduces mortality, length of 
hospitalization and thus might reduce the costs.
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todiseases, where patients are directly admitted to a highly 
specialized ward, with a multidisciplinary team, strict 
adherence to guidelines and easy access to special procedures 
(Fig. 1A). There are examples of established specialized 
care models for the treatment of stroke and acute coronary 
syndrome [1, 2]. 
On the other pathway, patients are referred to general 
medical wards (internal medicine or surgery), and, depending 
on the progression of the disease, some patients are transferred 
to specialized wards. If there is further deterioration, transfer 
to an intensive care unit may be necessary. We define this as 
the general medical care model. 
Outcomes for acute diseases can be significantly different 
depending on care, and there are examples of significantly 
improved outcomes for acute diseases treated in specialized 
centers. There is ample evidence that organized care for 
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stroke [1] and acute myocardial infarction with ST elevation 
in specialized centers have saved lives and reduced the 
burden of these diseases [2]. Based on this evidence, 
national and international stroke [3] and cardiology [4] 
associations organized care in specialized centers, with specific 
recommendations in their guidelines. 
Acute pancreatitis (AP) is the most common acute 
presentation in gastroenterology requiring hospital admission 
in the USA [5]. According to data obtained from the 
Hungarian National Health Insurance Fund, there is an 
estimated 5500 AP hospital admissions/year for Hungary’s 
population of 10 million. There have been significant efforts 
to improve outcomes and to reduce the disease burden in AP 
as suboptimal care can result in progression to severe forms 
of the disease, higher morbidity and mortality. The Working 
Group of the International Association of Pancreatology and 
the American Pancreatic Association (IAP/APA) updated 
and published evidence-based guidelines for the treatment 
of AP [6] most recently in 2013, and the American College of 
Gastroenterology (ACG) also published their guidelines [7] the 
same year. The Hungarian Pancreatic Study Group translated 
both and synthesized them in the Hungarian guidelines [8] 
in 2015. 
The IAP/APA guidelines suggest intensive care for patients 
with severe AP and referral to a specialized center [6]. In 
defining a center specialized for AP, the guidelines specify the 
need for intensive care facilities for organ replacement therapy, 
continuous access to interventional radiology, endoscopic 
retrograde cholangiopancreatography (ERCP), endoscopic 
ultrasonography and surgical expertise in the treatment of 
necrotizing AP [6].
The ACG guidelines recommend risk stratification to 
identify patients who will need early transfer to an intensive 
care unit [7]. Referral to a specialized center in the case of 
severe AP is also recommended in the Hungarian guidelines 
[8]. However, there is no recommendation in these guidelines 
regarding whether all AP (mild and moderate) should be 
referred to centers with specialized care after diagnosis at the 
emergency unit. There is convincing evidence on improved 
outcomes for AP in high-volume centers (more than 118 
admissions/year for AP), according to Singla et al. [9]. 
It is difficult to predict the severity of AP at the time of 
admission, and patients presenting with mild forms can 
develop fulminant AP within a few days. Current stratification 
systems for AP are unable to predict the course of the disease 
at the early stage unless the disease is severe at the time of 
admission. The revised Atlanta classification of AP severity 
is determined by clinical parameters recorded throughout 
the disease and provides disease severity in retrospect [10]. 
Therefore, it is not suitable for predicting the outcome. 
The guidelines for the treatment of AP [7-9] recommend 
that the risk factors, the clinical prognostic factors and the 
response to the treatment should be monitored to predict 
the outcome. However, a reliable prediction system based on 
admission parameters is yet to be developed for the accurate 
prediction of the clinical course of and outcome for AP. 
Until now, no evidence has been published for or against 
the treatment of AP of all severities in specialized pancreatic 
centers. 
Our aim was to investigate whether specialized care 
improves the outcomes for AP.
METHODS
The Hungarian Pancreatic Study Group was established 
in 2011 to improve care for pancreatic diseases. To date, 
the Hungarian Pancreatic Study Group has built up an 
international prospective registry for AP and organized five 
registered clinical trials to investigate AP under the acronyms 
PREPAST [11], APPLE [12], PINEAPPLE [13], GOULASH 
[14] and EASY [15].
Study design
In this observational cohort study, we analyzed and 
compared data from the prospectively collected AP Registry, 
specifically, outcomes, quality of care and costs for AP in 
two university hospitals with two different models for the 
management of AP. 
Treatment Center A fulfilled the criteria for a specialized 
center for AP. Patients were admitted directly to the specialized 
ward from regional emergency departments. Center A admits 
patients from nine high-volume emergency units in the region. 
The specialized center has an integrated care pathway for 
patients requiring care in the high dependency unit or intensive 
care unit (Fig. 1A).
Treatment Center B admits patients with AP to general 
internal medicine wards from the emergency department, and 
patients are transferred to the specialized pancreatic ward, if 
there is deterioration. Treatment Center B transfers patients 
from the emergency department to one of the five general 
internal medicine wards or to a surgical ward, or if indicated 
by the patient’s status, either to the tertiary pancreatic center 
or to the intensive care unit (Fig. 1B).
Both treatment centers (A and B) deal with high volumes, 
but their models of care for AP are different. Both institutions 
care for populations with nearly identical demographics.
Limitation
The study design and the differences between the two 
cohorts are potential sources of bias and limitation; therefore, 
both cohorts were carefully scrutinised through statistical 
analysis before comparing outcomes to ensure that they were 
comparable.
Ethical approval
The study was approved by the Scientific and Research 
Ethics Committee of the Medical Research Council (22254-
1/2012/EKU) on 15 August 2012 and conforms to the 1975 
Declaration of Helsinki ethical guidelines as reflected in a priori 
approval by the institution’s human research committee. The 
patients signed the relevant consent forms.
Statistical analyses
The demographics and the etiology in both samples were 
compared. To analyze the differences in the distribution of 
severity, complications (local and systemic), mortality and 
management (enteral feeding and antibiotic use) between the 
centers, we used Pearson’s chi-squared test or Fisher’s exact 
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test. We used the independent samples Student’s t-test for age 
and the Mann–Whitney U test for comparison of hospital stay. 
P values under 0.05 were considered statistically significant. 
Where the p value was less than 0.1 but higher than 0.05, we 
only regarded the result as a tendency. All statistical analyses 
were performed by IBM SPSS Statistics v 24.0 (IBM, New 
York, NY, USA). 
RESULTS
The best evidence in comparative medicine is always 
provided by the results from randomized clinical trials, as 
they ensure that there is no selection bias between cases and 
controls. However, in this observational trial, it was impossible 
to perform randomization, since there was only one model of 
care for AP in the two centers. In addition, these large centers 
are far away from each other; therefore, transfer of patients 
after randomization would not have been possible. Finally, and 
most importantly, randomization would have been unethical. 
The two university centers are located in the same region of 
Europe with an ethnically homogeneous population, and 98% 
of the patients approached gave their consent at both centers.
Demographic characteristics
Treatment Center A with specialized care for AP admitted 
195 patients, while treatment Center B treated 160 patients with 
AP in 2016 (Fig. 1A, B). A demographic analysis of the two 
cohorts showed no significant difference. Mean age was 57.02 
(±17.16) in Center A and 57.31 (±16.50) in Center B (p=0.872). 
The proportion of males was 56% in Center A and 57% in Center 
B (p=0.837). Age did not differ significantly in males or females 
between the two cohorts (male mean age in center A: 54.16 
±16.96; in Center B: 57.03±16.01, p=0.221; female mean age in 
Center A: 60.71 ±16.80; in Center B: 57.68 ±17.26, p=0.276).
Although it was not intentional, the cohorts were matched 
for age and sex (Fig. 2 A, B ). 
The etiology of AP was similar in both cohorts. The 
major causes were biliary stones, alcohol, and idiopathic 
Fig. 1. A: Patient pathways in the specialized high-volume center from different Emergency 
Units (ER); B: Patient pathways in the step-up care pathway institution from Territorial Internal 
Medical Departments (TIMD), Intensive Care Units (ICU), the Tertiary Pancreas Center (TPC) 
and the Surgical Department (SD), number of cases (n).
Fig. 2. A: The demographic characteristics and etiological factors of acute pancreatitis in the 
specialized high-volume center; B: The demographic characteristics and etiological factors of 
acute pancreatitis in the step-up care pathway institution.
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and hyperlipidemia, accounting for the vast majority in both 
centers (Fig. 2).
This similarity, along with the matched age and sex ratio, 
allowed us to compare the outcomes for AP in both cohorts and 
reduced the selection bias of this observational cohort study. 
Severity and mortality of AP
The distribution of the worst severity of AP was different in 
Centers A and B (Fig. 3 A, B). Center B had 67% more severe 
AP (n=19, 11.9%) than Center A (n=14, 7.1%); however, this 
was not statistically different (p=0.310), likely due to the small 
sample sizes, 14 patients in Center A and 19 in Center B. 
The mortality of all AP in Center B was six times higher 
(n=16, 6.25%) than in Center A (n=2, 1.03%), and this 
difference proved to be statistically significant, p=0.007. Severe 
AP showed a threefold increase of mortality in Center B (n=8, 
47.37% vs. n=2, 14.29%, p=0.067). There were no deaths from 
mild AP in either cohort.
The average hospital stay was significantly shorter in Center 
A (Me: 6 (IQR: 5–9) days vs. Me: 8 (IQR: 6–11) days, p=0.02) 
(Fig. 3 A, B). The subgroup analysis found shorter means of 
hospital stay for all grades of severity; however, it was only 
significant in mild AP, suggesting that mild cases of AP were 
discharged sooner from Center A.
Complications of AP
Our analysis found no differences between the local and 
systemic complications of AP between Centers A and B (n=43, 
23.1% vs. n=35, 21.8%, p=0.872, and n=21, 10.5% vs. n=27, 
16.9%, p=0.177, respectively). The detailed results are shown 
in Fig. 3C.
Interventions and therapy
There were no differences between Center A and B 
in the number of ERCP (n=85, 43.59% vs. n=59, 36.88%, 
p=0.143), necrosectomy (n=1, 0.5% vs. n=2, 1.25%, p=0.793) 
and radiological or endoscopic ultrasound-guided drainage 
procedures (n=8, 4.1% vs. n=2, 1.2%, p=0.118).
We found no differences in the number of ERCPs for 
biliary pancreatitis, n=69, 83% ERCPs in n=83 patients in 
Center A and n=45, 84.9% ERCPs in n=53 patients in Center 
B (p=0.817). The ERCPs in AP with biliary etiology were 
performed in n=60 mild, n=4 moderate, and n=5 severe AP 
cases in Center A and n=40, n=4 and n=1 in Center B. None 
of these were significantly different.
Quality of care and management
We investigated whether management of patients and 
adherence to the guidelines differed in the two centers. The 
best and most reliable management markers which we could 
identify were enteral feeding and the use of antibiotics (Fig. 
4 A, B).
More patients had enteral feeding in Center A than in 
Center B (n=179, 91.8% vs. n=36, 22.5%, p<0.001) (Fig. 4 A,B).
The use of antibiotics also differed; significantly fewer 
patients were treated with antibiotics in Center A in contrast 
to Center B (n=85, 43.6% vs. n=123, 76.9%, p<0.001) (Fig. 
4 A, B). A detailed analysis of antibiotic use demonstrated a 
Fig. 3. A: The distribution of disease severity, mortality and length of hospitalization (LOH) in 
the specialized high-volume center; B: The distribution of disease severity, mortality and length of 
hospitalization (LOH) in the step-up care pathway institution; C: Complications in the two centers. 
*significant difference; severe (SEV); moderate (MOD); number of cases (n).
Centralized care for acute pancreatitis 155
J Gastrointestin Liver Dis, June 2018 Vol. 27 No 2: 151-157
significant difference between the two centers with regard to 
mild and moderate AP (n=54, 63.5%, vs. n=83, 67.5%, p<0.05 
and n=18, 21.2%, vs. n=21, 17.1%, p=0.024). There was no 
difference in antibiotic use between the two centers with regard 
to severe AP (n=13, 15.3%, vs. n=19, 15.4%, p=0.424). Results 
are shown on Fig. 4C. 
Economic implications 
To understand the economic implications of the two 
different models of AP treatment, the average cost of 
management for 10 patients was calculated in both groups. The 
calculated average costs are based on the costs of medication, 
disposables, procedures and investigations. However, our 
calculation was limited by costs that could not be estimated, 
such as the costs of staff and hospital stay (Fig. 5). 
The average daily costs in both centers in subgroups of 
mild, moderate and severe AP are indicated with or without 
antibiotic treatment. Based on this estimate, the cost of 
treatment for AP is 25% lower in the specialized care model 
than in the general medical model.
DISCUSSION
We hypothesized that specialized care for AP in high-
volume centers is beneficial and measurable in both outcomes 
and costs. We analyzed comparable cohorts in both centers, 
without significant differences in their demographics. Both 
centers are tertiary referral institutions and university 
hospitals with the same level of medical expertise and skills. 
Funding for health care services in both centers is identical. 
The only significant difference in terms of AP is their model 
of management of AP. 
We believe that these prospectively collected data from 
the two cohorts are nearly as comparable as data from two 
branches of a randomized controlled trial, and we note 
that the latter would have been impossible and unethical to 
organize.
Fig. 4.  A: Managing acute pancreatitis (with antibiotics and enteral nutrition) in the specialized 
high-volume center; B: Managing acute pancreatitis (with antibiotics and enteral nutrition) in the 
step-up care pathway institution; C: Antibiotic use in the two centers for different severities of acute 
pancreatitis. Severe (SEV); moderate (MOD).
Fig. 5.  A: Costs of managing acute pancreatitis (AP) in the specialized, 
high-volume center; B: Costs of managing acute pancreatitis (AP) in 
the general medical center. This estimate does not include the costs 
of staff and hospital bed.
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There are multiple reasons we were able to show 
significantly improved outcomes, management and hospital 
stay in the specialized center. 
In our analysis, we found that lower mortality and shorter 
hospital stay were associated with significant differences in the 
practices between the two centers. The specialized center with 
better outcomes used significantly more often enteral feeding 
and fewer antibiotics. However, there was no difference in the 
number of endoscopic or radiological procedures.
Center B followed the guidelines of enteral tube feeding 
more rigorously than Center A and limited the use of enteral 
tube feeding to manage patients with severe pancreatitis and 
predicted severe AP. We acknowledge that Center A used 
more enteral feeding to treat AP than strict adherence to the 
guidelines [8] would have suggested. There are many studies 
with evidence for early feeding in AP, but they compared enteral 
nutrition or enteral tube feeding vs. nil per os management. We 
note that there is a lack of clinical trials providing evidence and 
information on early oral vs. enteral tube feeding.
Petrov et al. [16] reported the benefits of enteral tube 
feeding in a randomized control trial compared to the nil per os 
approach and concluded that it leads to less oral food intolerance. 
Furthermore, our recent meta-analysis by Marta et al. [17] 
confirmed this. In addition, as a leading pancreatic clinical 
research unit, Center A is conducting a long-term randomized 
clinical trial investigating the benefits of early high-energy enteral 
tube nutrition in AP [14]. Prediction of severe AP is difficult 
in the early phase of the disease (24–48 hours). Enteral tube 
feeding may have the potential to prevent severe AP, and this is 
one of the foci of our research. Patients in Center A started oral 
feeding once their abdominal pain resolved, and enteral tube 
feeding often lasted less than one or two days in cases of mild 
and moderate AP.
Moraes et al. [18] and Larino-Noia et al. [19] showed that 
early oral re-feeding was safe and well tolerated, but neither 
study compared it to enteral tube feeding.
Finally, yet importantly, none of the guidelines precludes 
the option of enteral tube feeding in mild or moderate AP.
In Center A, with high-volume specialized care, patients are 
reviewed within 24 hours by gastroenterologists with expertise in 
AP, and patients are looked after by that same team throughout 
their hospital stay. Therefore, their continuity of care is optimal.
In Center B, patients are admitted to a general internal 
medicine unit, often without expertise in gastroenterology. 
We believe that this profound difference results in a significant 
delay in decision making in the treatment of AP, translated 
to poorer mortality. Patients transferred between medical 
teams often receive more fragmented treatment, and this 
approach increases the possibility of further delays and risks 
of complications as well.
Other possible factors are suboptimal knowledge and 
adherence to the AP guidelines among physicians without 
expertise and low case numbersof AP. 
Based on these results, organized specialized care for AP 
in Hungary could shorten the hospital stay by 1,100 days (2 
days/patient) and could save 275 lives (5% more) in a single 
year. Specialized care could reduce the costs of medications, 
disposables, procedures and investigations by 25%.
CONCLUSION
Managing AP in a high-volume center can potentially 
decrease disease severity, reduce the need for medications, 
improve mortality, shorten hospital stay and reduce costs of 
care. Therefore, further in-depth analysis would be warranted 
to establish whether AP should be managed in high-volume 
specialized centers.
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